HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced that new clinical trial data concerning the safety and efficacy of the Company’s NX-1207 for benign prostatic hyperplasia (BPH) will be presented at the Annual Meeting of the Western Section of the American Urological Association Meeting being held in Monterey, CA from October 26 to 30, 2008. The podium paper is authored by leading independent clinical research investigators participating in the U.S. clinical trials of NX-1207.
